Anidulafungin: a new echinocandin for candidal infections

Authors: de la Torre, Pola; Reboli, Annette C

Source: Expert Review of Anti-Infective Therapy, Volume 5, Number 1, February 2007 , pp. 45-52(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Anidulafungin, a new echinocandin, has recently been approved for the treatment of esophageal candidiasis, candidemia and other forms of invasive candidiasis, such as peritonitis and intra-abdominal abscesses in non-neutropenic patients. It is fungicidal against Candida spp. including those that are azole- and polyene-resistant and fungistatic against Aspergillus spp. Owing to its poor oral bioavailability it can only be administered intravenously. Its pharmacokinetics allow for once-daily dosing and a steady state concentration is easily achieved on day 2 following a loading dose of double the maintenance dose on day 1. It does not need adjustment for hepatic or renal insufficiency; there are no known drug interactions and it has a favorable tolerability profile. Its mechanism of action, which differs from other classes of antifungals, should prevent cross-resistance with azoles and polyenes.

Keywords: anidulafungin; candidemia; echinocandin; esophageal candidiasis

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14787210.5.1.45

Publication date: 2007-02-01

More about this publication?

Expert Review of Anti-infective Therapy provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites